belantamab mafodotin (Blenrep)

following a full submission assessed under the orphan equivalent medicine process:

belantamab mafodotin (Blenrep®) is not recommended for use within NHSScotland.

Indication under review: in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy including lenalidomide.

In an open-label phase III study in patients with relapsed or refractory multiple myeloma who had previously received lenalidomide, belantamab mafodotin in combination with pomalidomide plus dexamethasone was associated with statistically significant improvements in progression-free survival compared with an immunomodulatory agent in combination with a proteasome inhibitor and a glucocorticoid.

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.